Dr. Borgen Discusses the Patents on BRCA1 and BRCA2

Patrick Borgen, MD
Published Online: Monday, Apr 08, 2013

Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, discusses the patents on BRCA1 and BRCA2.

Of the 20,000 human genes, about 4,000 are protected under patent or intellectual property rights, Borgen says, making BRCA1 and BRCA2 not all that unique. The American Civil Liberties Union has filed lawsuits arguing that these patents infringe upon the rights of researcher, geneticists, and patients.

As a practicing physician, Borgen has done research with BRCA1 and BRCA2 and has never been impeded by Myriad Genetics. In some ways, Borgen feels that physicians are lucky to have a singe reference laboratory to trust.

Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, discusses the patents on BRCA1 and BRCA2.

Of the 20,000 human genes, about 4,000 are protected under patent or intellectual property rights, Borgen says, making BRCA1 and BRCA2 not all that unique. The American Civil Liberties Union has filed lawsuits arguing that these patents infringe upon the rights of researcher, geneticists, and patients.

As a practicing physician, Borgen has done research with BRCA1 and BRCA2 and has never been impeded by Myriad Genetics. In some ways, Borgen feels that physicians are lucky to have a singe reference laboratory to trust.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
13th Annual School of Breast Oncology® OnlineJan 29, 201724.25
Clinical Vignette Series: 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 19, 20173.0
Publication Bottom Border
Border Publication